Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients

Table 2

Comparison of clinicopathological characteristics of patients with pure DCIS between this and published studies.

Characteristics	Subgroup	Our study	SEER 2015	NSABP-B24	EORTC	SweDCIS	B17	Canada	Nottingham 2019	UCSD 2020
Year of research	—	2005–2015	1988–2011	1986–2009	1986–1996	1987–1999	1985–1990	1994–2003	1990–2012	2010–2016
No. of patients	—	617	108.196	2.061	1010	1046	790	571	651	1540
Detection method	Symptomatic	58.7%	—	8.7%	27.2%	27.6%	8.1%	—	48%	—
	Screening	39.4%	—	82.6%	71.6%	72.4%	80.8%	—	52%	—
Age (years)	≤50 y	56.7%	33.9%	33.5%	—	24.1%	33.3%	19.3%	—	—
	＞50 y	43.3%	66.1%	66.5%	—	75.9%	66.7%	80.7%	—	—
Tumor size (cm)	≤2.0 cm	78.1%	77.0%	94.2%	91.2%	67.5%	87.8%	—	—	—
	＞2.0 cm	21.9%	23.0%	4.3%	8.8%	21.8%	8.9%	—	—	—
Nuclear grade	Low-intermediate	77.4%	54.0%	54.0%	62.3%	50.2%	—	67.7%	39.2%	57.3%
	High	20.9%	46.0%	42.3%	37.7%	49.8%	—	32.3%	60.8%	42.7%
ER status	Positive	76.3%	42.5%	28.6%	52.7%	—	—	94.7%	75.3%	84.2%
	Negative	19.3%	8.2%	8.3%	19.8%	—	—	5.3%	24.7%	15.5%
	NA	4.4%	49.2%	63.1%	27.5%	—	—	—	—	0.3%
PR status	Positive	69.0%	—	—	44.3%	—	—	—	46.7%	74.2%
	Negative	26.3%	—	—	23.1%	—	—	—	53.3%	25.2%
	NA	3.7%	—	—	32.7%	—	—	—	—	0.6%

SEER: surveillance, epidemiology, and end results; NSABP: National Surgical Adjuvant Breast and Bowel Project; EORTC: European Organisation for Research and Treatment of Cancer; SweDCIS: Swedish ductal carcinoma in situ; UCSD: University of California, San Diego; other abbreviations as in Table 1.